Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
- PMID: 27863752
- PMCID: PMC5119658
- DOI: 10.1016/j.bjhh.2016.07.006
Hematopoietic stem cell mobilization for autologous transplantation in multiple myeloma patients previously exposed to cyclophosphamide, thalidomide, and dexamethasone: is granulocyte-colony stimulating factor alone enough?
References
-
- Shah N., Callander N., Ganguly S., Gul Z., Hamadani M., Costa L. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2015;21:1155–1166. - PubMed
-
- Giralt S., Stadtmauer E.A., Harousseau J.L., Palumbo A., Bensinger W., Comenzo R.L. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) Leukemia. 2009;23:1904–1912. - PubMed
-
- Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009;43:181–195. - PubMed
-
- Crusoe E.Q., Higashi F., Martinez G.A., Barros J.C., Bellesso M., Rossato M. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a cyclophosphamide, thalidomide and dexamethasone regimen? Rev Bras Hematol Hemoter. 2016;38 - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
